Biomax Informatics Collaborates with Pierre Fabre on Therapeutic Antibody Development
Biomax Informatics AG and Pierre Fabre announced that they have entered into a collaboration to create an integrated antibody sequence and knowledge database.
Biomax Informatics AG and Pierre Fabre announced that they have entered into a collaboration to create an integrated antibody sequence and knowledge database. Following a successful pilot project, Pierre Fabre has licensed Biomax's BioXM Knowledge Management Environment and agreed on a continuous refinement and expansion of the system for comprehensive support of their antibody development process.
Biomax used the BioXM Knowledge Management Environment to configure a centralized antibody sequence and knowledge base that supports Pierre Fabre's antibody discovery process. The knowledge base comprises sophisticated sequence analysis and storage, a platform to share in-house data and algorithms, public data, and both public and third-party algorithms. Pierre Fabre researchers have adopted the platform to collect and generate further knowledge.â¨â¨
Source: Biomax Informatics
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
